Earnings call transcript: ResMed's Q4 2025 shows strong EPS, stock dips post-call

ResMed Inc. (RMD) reported Q4 FY2025 EPS of $2.55, surpassing analyst expectations, though revenue of $1.3 billion fell slightly short of forecasts, leading to a 1.98% aftermarket stock decline despite 10% top-line growth and a 23% increase in non-GAAP diluted EPS year-over-year. The company demonstrated robust operational performance with gross margin expanding by 230 basis points to 61.4% and announced a 13% increase in its quarterly dividend alongside plans for $150 million in quarterly share buybacks for FY2026. Management expressed confidence in ResMed's market leadership, strategic investments in innovation, and ability to navigate evolving market dynamics, including the anticipated CMS competitive bidding program.

Analysis

ResMed Inc. (RMD) reported a bifurcated fourth-quarter fiscal year 2025, characterized by strong underlying operational performance overshadowed by a top-line miss against forecasts. The company posted an EPS of $2.55, a 2.82% positive surprise, but revenue fell short of expectations, triggering a 1.98% decline in the stock during aftermarket trading. Despite this market reaction, the fundamentals appear robust; group revenue grew 10% year-over-year to $1.35 billion, and non-GAAP diluted EPS increased by a significant 23%. A key highlight was the 230 basis point expansion in gross margin to 61.4%, driven by manufacturing and logistics efficiencies, signaling successful execution on cost controls. Management projected continued strength with FY2026 gross margin guidance of 61% to 63%.

Forward-looking statements from the earnings call underscore a confident strategic posture focused on both shareholder returns and long-term growth. The company announced a 13% increase in its quarterly dividend and a plan to execute $150 million in share buybacks per quarter, leveraging a strong free cash flow of $1.7 billion for the fiscal year. Strategically, ResMed is investing to expand its ecosystem beyond core devices through acquisitions like Vertuox to build out its home sleep apnea testing capabilities, and is ramping up direct-to-consumer marketing and AI integration. Management also addressed key investor concerns, framing the re-implementation of the CMS competitive bidding program as a manageable challenge based on historical experience and viewing the rise of GLP-1 medications as a net positive tailwind for patient diagnosis and therapy adoption.

Key Decisions for Investors

• Investors should weigh the negative market sentiment from the revenue miss against the firm's strong operational execution, evidenced by a 230 basis point gross margin expansion and a 23% increase in non-GAAP EPS.
• The commitment to return capital, via a 13% dividend hike and a new $150 million quarterly share buyback program, offers a tangible yield and signals management's confidence in future cash flow generation.
• Monitor the progress of the company's strategic acquisitions like Vertuox and the ROI on its direct-to-consumer marketing campaigns, as these are critical levers for driving future growth and expanding the patient funnel.
• Consider the potential regulatory impact of the CMS competitive bidding program, but note management's experienced and relatively confident stance on navigating these policies without significant disruption.